Official Journals By StatPerson Publication


Introduction: Misoprostol has proven its efficacy as an effective abortifacient for the second trimester termination of pregnancy. It is being successfully used through all the routes i.e. sublingual, oral and vaginal and in different regimens with the induction abortion interval varying from 12 h to as high as 33 h. Aims and Objectives: To Study the Efficacy of Mifepristone with misoprostol over misoprostol alone in medical termination of Pregnancy Methodology: This was a hospital based study in patients attending the department of Obstretics and Gynecology of teaching hospitals attached to Bangalore Medical College, Bangalore (viz. Bowring and Lady Curzon Hospital and Vanivilas Hospital) who needed MTP. Out of 100 Pregnant Women 50 pregnant women given oral mifepristone 200mg followed by vaginal misoprostol 400 microgram after 48 hours and one hour of that 200 microgram of oral misoprostol. 50 pregnant women given 600 microgram vaginal misoprostol alone at a time The statistical analysis done by unpaired t-test. Result: Complete abortion was achieved in 88% (44) of the patients in misoprostol alone regimen. Complete abortion was achieved in 96% (48) of the patinets in combination regimen. Overall complete abortion was achieved in 92 patients in our study. Failure rate was observed more in Misoprostol alone group i.e. 12.0% as compared to Misoprostol+Mifepristone group i.e. 4.0%. Mean Time to Induction to Abortion was significantly less in Mifepristone with misoprostol than misoprostol alone group. Conclusion: From our study it can be concluded that the combination of Mifepristone with misoprostol is superior to misoprostol alone with respect to less failure rate and Mean Time to Induction to Abortion in both Primi and Multi Gravidity.

Keywords: Mifepristone, Misoprostol, Medical termination of Pregnancy.



STATPERSON PUBLISHING GROUP | Aurangabad | Maharashtra |2016 | INDIA
© Copyright 2016 Statperson Publishing Corporation. a division of Statperson Consultancy.
All Rights Reserved.